Markus Weiler

5.6k total citations · 1 hit paper
91 papers, 3.3k citations indexed

About

Markus Weiler is a scholar working on Molecular Biology, Genetics and Neurology. According to data from OpenAlex, Markus Weiler has authored 91 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 33 papers in Genetics and 17 papers in Neurology. Recurrent topics in Markus Weiler's work include Glioma Diagnosis and Treatment (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (14 papers) and Neurogenetic and Muscular Disorders Research (13 papers). Markus Weiler is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (14 papers) and Neurogenetic and Muscular Disorders Research (13 papers). Markus Weiler collaborates with scholars based in Germany, United States and Switzerland. Markus Weiler's co-authors include Wolfgang Wick, Michael Weller, Martin Bendszus, Michael Platten, Mirko Pham, Sabine Heiland, Andreas von Deimling, Philipp Bäumer, Jörg Wischhusen and Guido Reifenberger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Markus Weiler

87 papers receiving 3.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MGMT testing—the challenges for biomarker-based glioma treatment

2014 393 citations Wolfgang Wick, Michael Weller et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Markus Weiler	1.4k	1.2k	665	663	534	91	3.3k
Melike Pekmezci	1.3k 1.0×	1.4k 1.2×	678 1.0×	514 0.8×	836 1.6×	101	4.0k
Yukihiko Sonoda	1.6k 1.2×	2.2k 1.8×	492 0.7×	596 0.9×	642 1.2×	224	4.6k
Keishi Makino	1.5k 1.1×	1.4k 1.1×	701 1.1×	1.0k 1.5×	583 1.1×	95	4.2k
Takanori Ohnishi	1.1k 0.8×	715 0.6×	322 0.5×	480 0.7×	485 0.9×	146	3.5k
Nils Ole Schmidt	1.6k 1.2×	1.1k 0.9×	230 0.3×	689 1.0×	489 0.9×	134	3.7k
Joerg‐Christian Tonn	729 0.5×	1.7k 1.4×	565 0.8×	620 0.9×	479 0.9×	111	3.6k
Alessandro Della Puppa	938 0.7×	1.5k 1.2×	263 0.4×	543 0.8×	595 1.1×	172	3.2k
Koji Yoshimoto	1.1k 0.8×	1.4k 1.1×	1.1k 1.6×	296 0.4×	859 1.6×	229	3.4k
Marica Eoli	1.0k 0.8×	2.0k 1.7×	389 0.6×	693 1.0×	766 1.4×	152	3.8k
Sandeep Kunwar	778 0.6×	1.4k 1.2×	339 0.5×	411 0.6×	273 0.5×	82	4.1k

Countries citing papers authored by Markus Weiler

Since Specialization

Citations

This map shows the geographic impact of Markus Weiler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Weiler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Weiler more than expected).

Fields of papers citing papers by Markus Weiler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Weiler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Weiler. The network helps show where Markus Weiler may publish in the future.

Co-authorship network of co-authors of Markus Weiler

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Weiler. A scholar is included among the top collaborators of Markus Weiler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Weiler. Markus Weiler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Warnken, Uwe, Dirk C. Hoffmann, Mirjam Korporal‐Kuhnke, et al.. (2025). Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen. Journal of Neurology. 272(4). 270–270. 2 indexed citations

Cordts, Isabell, Tobias Keßler, Maren Freigang, et al.. (2025). Long-Term Dynamics of CSF and Serum Neurofilament Light Chain in Adult Patients With 5q Spinal Muscular Atrophy Treated With Nusinersen. Neurology. 104(5). e213371–e213371. 6 indexed citations

Jahromi, Leila Pourtalebi, Jennifer Munkert, Marcus Koch, et al.. (2025). Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome. Small. 22(16). e2502551–e2502551.

Täger, Tobias, Matthias Mueller‐Hennessen, Markus Weiler, et al.. (2024). Interpretation of Elevated Baseline Concentrations and Serial Changes of High-Sensitivity Cardiac Troponin T in Confirmed Muscular Dystrophies. ESC Heart Failure. 11(6). 3732–3741. 1 indexed citations

Saffari, Afshin, Claire Cannet, Astrid Blaschek, et al.. (2024). Identification of Biochemical Determinants for Diagnosis and Prediction of Severity in 5q Spinal Muscular Atrophy Using 1H-Nuclear Magnetic Resonance Metabolic Profiling in Patient-Derived Biofluids. International Journal of Molecular Sciences. 25(22). 12123–12123. 2 indexed citations

Hegenbart, Ute, Stefan Schönland, Jan Purrucker, et al.. (2024). T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy. Amyloid. 31(4). 309–317.

Conceição, Isabel, John L. Berk, Markus Weiler, et al.. (2024). Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. Journal of Neurology. 271(10). 6655–6666. 4 indexed citations

Siepen, Fabian aus dem, Selina Hein, Christian Nagel, et al.. (2024). Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis. Journal of Clinical Medicine. 13(8). 2257–2257. 2 indexed citations

Keßler, Tobias, et al.. (2023). Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures. European Journal of Neurology. 31(1). e16099–e16099. 9 indexed citations

10.

Jacobi, Heike, Markus Weiler, Sabine Heiland, et al.. (2023). Peripheral nerve involvement in hereditary spastic paraplegia characterized by quantitative magnetic resonance neurography. European Journal of Neurology. 30(8). 2442–2452. 2 indexed citations

11.

Sturm, Volker, Markus Weiler, Brigitte Wildemann, et al.. (2023). Microstructural changes of peripheral nerves in early multiple sclerosis: A prospective magnetic resonance neurography study. European Journal of Neurology. 31(2). e16126–e16126. 1 indexed citations

12.

Michel, Laura L., Manuel Feißt, Michael O. Breckwoldt, et al.. (2022). 1552O Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial. Annals of Oncology. 33. S1257–S1258. 3 indexed citations

13.

Hahn, Andreas, René Günther, Albert C. Ludolph, et al.. (2022). Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet Journal of Rare Diseases. 17(1). 276–276. 20 indexed citations

14.

Müller, J.H., Markus Weiler, Andreas Schneeweiß, et al.. (2021). Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial. British Journal of Cancer. 125(7). 955–965. 46 indexed citations

15.

Ungerer, Matthias N., Ernst Hund, Jan Purrucker, et al.. (2020). Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid. 28(2). 91–99. 12 indexed citations

16.

Dohrn, Maike F., Michaela Auer‐Grumbach, Ralf Baron, et al.. (2020). Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature. Journal of Neurology. 268(10). 3610–3625. 19 indexed citations

17.

Pfeiffenberger, Jan, Christine M. Lohse, Daniel Gotthardt, et al.. (2018). Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment. Journal of Inherited Metabolic Disease. 1 indexed citations

18.

Zhu, Zhe, Muhammad Amir Khan, Markus Weiler, et al.. (2014). Targeting Self-Renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged Survival. Cell stem cell. 15(2). 185–198. 91 indexed citations

19.

Wick, Wolfgang, Christoph Meisner, Bettina Hentschel, et al.. (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 81(17). 1515–1522. 173 indexed citations

20.

Radbruch, Alexander, Benedikt Wiestler, Kira Lutz, et al.. (2012). Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging. European Journal of Radiology. 82(3). 552–556. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact